Healthcare Purchasing News, a publication for supply chain leadership, recently featured Cook Medical’s antimicrobial-impregnated central venous catheters. Dan Sirota discussed Spectrum® technology with journalist Susan Cantrell and explained both the patient and financial impact of using Spectrum.
“Cook Medical’s Spectrum catheters are impregnated with minocycline and rifampin to protect patients against CLABSI, a common and potentially fatal hospital-acquired infection,” said Dan Sirota, Vice President, Interventional Radiology and Critical Care, Cook Medical, Bloomington, IN. “In a challenging clinical environment, a hospital that switches to a minocycline+rifampin-impregnated catheter can expect to see a decrease in CLABSI rates, attributable mortality, and CLABSI-related costs.”
“What might not be so apparent,” said Sirota, “is that high-performing hospitals can switch to Spectrum to drive incremental improvements in CLABSI rates and still achieve substantial reductions in mortality and cost. For example, in a hospital that places 100 CVCs per month with an average dwell time of 7 days1 and an infection rate of 3.3/1,000 catheter-days, a reduction by 50% would save that hospital 112 bed-days and $231,700 annually.”
The article on infection prevention in IV-site care aims to better patient care by providing information on technologies that can reduce infection rates. The full article can be accessed in the January issue of Healthcare Purchasing News oronline.
1Advani S, Reich NG, Sengupta A, et al. Central line-associated bloodstream infection in hospitalized children with peripherally inserted central venous catheters: extending risk analyses outside the intensive care unit. Clin Infect Dis.2011;52(9):1108-1115.